0.75% bupivacaine + .75% bupivacaine + .75% bupivacaine
ApprovedTerminated 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
SI Joint Pain
Conditions
SI Joint Pain
Trial Timeline
Apr 22, 2013 → Sep 30, 2014
NCT ID
NCT01874236About 0.75% bupivacaine + .75% bupivacaine + .75% bupivacaine
0.75% bupivacaine + .75% bupivacaine + .75% bupivacaine is a approved stage product being developed by SI-BONE for SI Joint Pain. The current trial status is terminated. This product is registered under clinical trial identifier NCT01874236. Target conditions include SI Joint Pain.
Hype Score Breakdown
Clinical
30
Activity
20
Company
2
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01874236 | Approved | Terminated |
Competing Products
6 competing products in SI Joint Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| oxycodone CR + oxycodone IR + Tapentadol ER (CG5503) + Tapentadol IR (CG5503) + Tapentadol IR (CG5503) + placebo + placebo | Johnson & Johnson | Phase 3 | 77 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1/2 | 41 |
| etanercept + placebo | Pfizer | Phase 2 | 51 |
| VANCOMYCIN + CEFTRIAXONE + CLINDAMYCIN + SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE) + FLUOROQUINOLONE + LINEZOLID + RIFAMPIN | Pfizer | Phase 2 | 51 |
| HOE140 Icatibant | Sanofi | Phase 2 | 51 |
| Methylprednisoloneacetate + Lidocaine | Lundbeck | Phase 2 | 49 |